During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.
How to Recognize, Diagnose, and Treat Patients With BPDCN
During a live event, Taha Al-Juhaishi, MD, discussed his experience treating blastic plasmacytoid dendritic cell neoplasm and getting patients to allogeneic transplant.
During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.
During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic cell neoplasm.
Marlise R. Luskin, MD, MSCE, discusses the vigilant monitoring required for capillary leak syndrome with tagraxofusp in BPDCN.
Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.
Marlise R. Luskin, MD, MSCE, discusses the trial of tagraxofusp in BPDCN, which showed high response rates and overall survival.
During a Case-Based Roundtable® event, Pinkal Desai, MD, MPH, discusses the presentation of blastic plasmacytoid dendritic cell neoplasm vs other diseases in a patient case.
During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses the adverse events, like capillary leak syndrome, that come with the use of tagraxofusp when treating patients with blastic plasmacytoid dendritic cell neoplasm in the second article of a 2-part series.
During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.
During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, moderated discussion of physicians' familiarity with diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, asked physicians about their experiences with patients with hematological malignancies with skin manifestations, and how to diagnose and work up these patients. This is the first of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the data behind tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.
Naveen Pemmaraju, MD discusses the long-term results of the STML-401-0114 trial that demonstrated the benefits of tagraxofusp-ezrs as a monotherapy for patients with blastic plasmacytoid dendritic cell neoplasms.
Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.